Literature DB >> 32567021

Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.

Ran Li1, Xing Wan2, Timo M Takala2, Per E J Saris2.   

Abstract

The yeast Saccharomyces boulardii is well known for its probiotic effects such as treating or preventing gastrointestinal diseases. Due to its ability to survive in stomach and intestine, S. boulardii could be applied as a vehicle for producing and delivering bioactive substances of interest to human gut. In this study, we cloned the gene lecC encoding the antilisterial peptide leucocin C from lactic acid bacterium Leuconostoc carnosum in S. boulardii. The constructed S. boulardii strain secreted a peptide, which had molecular weight corresponding to leucocin C in SDS-PAGE. The peptide band inhibited Listeria monocytogenes in gel overlay assay. Likewise, concentrated S. boulardii culture supernatant inhibited the growth of L. monocytogenes. The growth profile and acid tolerance of the leucocin C secreting S. boulardii were similar as those of the strain carrying the empty vector. We further demonstrated that the cells of the leucocin C producing S. boulardii efficiently killed L. monocytogenes, also without antibiotic selection pressure. These results showed that antilisterial activity could be added to the arsenal of probiotic activities of S. boulardii, demonstrating its potential as a carrier for therapeutics delivery.

Entities:  

Keywords:  Bacteriocin; Heterologous expression; Leucocin C; Probiotic yeast; Saccharomyces boulardii

Mesh:

Substances:

Year:  2021        PMID: 32567021      PMCID: PMC7904741          DOI: 10.1007/s12602-020-09676-1

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  49 in total

1.  High efficiency electroporation of ligated DNA into bacteria.

Authors:  E R Zabarovsky; G Winberg
Journal:  Nucleic Acids Res       Date:  1990-10-11       Impact factor: 16.971

2.  [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS].

Authors:  T Saint-Marc; L Rossello-Prats; J L Touraine
Journal:  Ann Med Interne (Paris)       Date:  1991

3.  Tricine-SDS-PAGE.

Authors:  Hermann Schägger
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.

Authors:  Bruno Douradinha; Viviane C B Reis; Matthew B Rogers; Fernando A G Torres; Jared D Evans; Ernesto T A Marques
Journal:  Bioengineered       Date:  2013-09-05       Impact factor: 3.269

5.  Improved antimicrobial activities of synthetic-hybrid bacteriocins designed from enterocin E50-52 and pediocin PA-1.

Authors:  Santosh Kumar Tiwari; Katia Sutyak Noll; Veronica L Cavera; Michael L Chikindas
Journal:  Appl Environ Microbiol       Date:  2014-12-19       Impact factor: 4.792

6.  Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Authors:  S M Klein; G W Elmer; L V McFarland; C M Surawicz; R H Levy
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

7.  Characterization of plasmid burden and copy number in Saccharomyces cerevisiae for optimization of metabolic engineering applications.

Authors:  Ashty S Karim; Kathleen A Curran; Hal S Alper
Journal:  FEMS Yeast Res       Date:  2012-11-20       Impact factor: 2.796

8.  The establishment of Saccharomyces boulardii surface display system using a single expression vector.

Authors:  Tiantian Wang; Hui Sun; Jie Zhang; Qing Liu; Longjiang Wang; Peipei Chen; Fangkun Wang; Hongmei Li; Yihong Xiao; Xiaomin Zhao
Journal:  Fungal Genet Biol       Date:  2013-12-02       Impact factor: 3.495

9.  Draft Genome Sequence of the Probiotic Yeast Saccharomyces cerevisiae var. boulardii Strain ATCC MYA-796.

Authors:  T M Batista; E T A Marques; G R Franco; B Douradinha
Journal:  Genome Announc       Date:  2014-12-18

Review 10.  Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review.

Authors:  Mduduzi Paul Mokoena
Journal:  Molecules       Date:  2017-07-26       Impact factor: 4.411

View more
  5 in total

1.  High-Titer Production of the Fungal Anhydrotetracycline, TAN-1612, in Engineered Yeasts.

Authors:  Pedro A Baldera-Aguayo; Arden Lee; Virginia W Cornish
Journal:  ACS Synth Biol       Date:  2022-06-14       Impact factor: 5.249

2.  Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.

Authors:  Yerin Jin; Sora Yu; Jing-Jing Liu; Eun Ju Yun; Jae Won Lee; Yong-Su Jin; Kyoung Heon Kim
Journal:  Microb Cell Fact       Date:  2021-08-18       Impact factor: 5.328

Review 3.  Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases.

Authors:  Karla Cristina P Cruz; Laura O Enekegho; David T Stuart
Journal:  Front Bioeng Biotechnol       Date:  2022-05-17

4.  The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota.

Authors:  Yongrong Zhang; Ashley Saint Fleur; Hanping Feng
Journal:  Gut Microbes       Date:  2022 Jan-Dec

5.  Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review.

Authors:  Haydee Eliza Romero-Luna; Adrián Hernández-Mendoza; Aarón Fernando González-Córdova; Audry Peredo-Lovillo
Journal:  Food Chem X       Date:  2021-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.